Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.
The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.
Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.
The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.
Immunome (Nasdaq: IMNM) announced its Q3 2024 financial results and provided a business update. The company reported a net loss of $47.1 million for the quarter ended September 30, 2024, with cash, cash equivalents, and marketable securities totaling $240.1 million, providing a cash runway into 2026. R&D expenses were $37.2 million, and G&A expenses were $9.5 million. Key pipeline updates include the completion of full enrollment for the Phase 3 RINGSIDE Part B study of AL102 for desmoid tumors, with topline data expected in H2 2025. IND submissions for IM-1021 and IM-3050 are anticipated in Q1 2025. The discovery team is focused on discovering ADCs targeting novel cancer therapy targets, highlighting the potential of HC74, a proprietary TOP1 payload.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. Clay Siegall, PhD, President and CEO, will engage in a fireside chat on Wednesday, November 13th at 10:30am Eastern Time. The presentation will be accessible via live audio webcast through the company's website's Investor Relations section, with a replay available for approximately 30 days post-event.
Immunome (Nasdaq: IMNM) announced that its Compensation Committee granted inducement awards to 14 new employees on October 31, 2024. The awards consist of non-statutory stock options to purchase 378,800 shares of common stock under the Company's 2024 Inducement Plan. The options have an exercise price of $11.47 per share, matching the Company's closing price on October 31. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Immunome (NASDAQ: IMNM) presented preclinical data for IM-1021, its ROR1-targeted antibody-drug conjugate, and its proprietary payload HC74 at the 36th EORTC-NCI-AACR Symposium. IM-1021 demonstrated superior efficacy compared to zilovertamab vedotin in mantle cell lymphoma and triple-negative breast cancer models. HC74 showed better potency than deruxtecan across 89 cancer cell lines, with improved hepatocyte clearance and maintained effectiveness in chemotherapy-resistant cells. The company plans to submit an IND application to FDA in Q1 2025.
Immunome (Nasdaq: IMNM) announced it will present a poster on the preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium in Barcelona on October 24, 2024. The presentation, titled 'Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload,' will be delivered by Robert Lawrence, Director of Biology at Immunome.
The company plans to submit an Investigational New Drug (IND) application for the IM-1021 program to the FDA in the first quarter of 2025. Following the presentation, the poster will be available on Immunome's website in the 'Events & Presentations' section.
Immunome (Nasdaq: IMNM) has appointed Roee Shahar as Executive Vice President, Commercial. Shahar brings over 20 years of experience in launching and commercializing oncology and hematology products from his roles at Seagen, Pfizer, and Eli Lilly & Company. This appointment strengthens Immunome's team in developing targeted oncology therapies.
CEO Clay Siegall highlighted Shahar's expertise in advancing the company's portfolio, particularly AL102, a gamma secretase inhibitor in Phase 3 trials for desmoid tumors. Shahar expressed his commitment to addressing the challenges posed by desmoid tumors, which can cause debilitating pain, deformity, and life-threatening organ damage.
Prior to joining Immunome, Shahar held leadership positions at Pfizer and Seagen, managing hematology portfolios and overseeing commercial activities for products like Adcetris® and Tivdak®. He also served as Marketing Director at Eli Lilly, leading the company's largest oncology brand, Alimta®.
Immunome (Nasdaq: IMNM), a biotechnology company focused on developing targeted cancer therapies, announced the granting of inducement awards to 25 new employees on October 3, 2024. The Compensation Committee approved nonstatutory stock options to purchase 851,400 shares of common stock under the Company's 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $13.43 per share, equal to the Company's closing sales price on October 3, 2024. However, options to purchase 250,000 shares will have an exercise price equal to the closing sales price on the date the grantee's employment begins. The options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over 36 months, subject to continued employment.
Immunome, Inc. (Nasdaq: IMNM) has announced that it will present updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress in Barcelona, September 13-17, 2024. The presentation will be in poster format, titled 'Updated Results of the RINGSIDE Phase 2 Trial and Open-Label Extension of AL102 for the Treatment of Desmoid Tumors' (Abstract #1766P), presented by Dr. Bernd Kasper on September 14, 2024.
Notably, enrollment in the Phase 3 portion of RINGSIDE was completed in February 2024, with topline data expected in the second half of 2025. The poster will be available on Immunome's website after the presentation.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Clay Siegall, PhD, will engage in a fireside chat on Wednesday, September 4, 2024, at 5:35 P.M. Eastern Time.
Interested parties can access the live audio webcast of this presentation through the Investor Relations section of Immunome's website at www.immunome.com. Following the live presentation, a replay of the webcast will be available for approximately 30 days.
Immunome (Nasdaq: IMNM) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Pipeline Progress: Full enrollment completed for Phase 3 RINGSIDE Part B study of AL102 for desmoid tumors, with topline data expected in H2 2025. INDs for IM-1021 and IM-3050 anticipated in Q1 2025.
- Financial Position: Cash, cash equivalents, and marketable securities totaled $278.4 million as of June 30, 2024, with runway expected into 2026.
- Q2 2024 Results: R&D expenses were $29.1 million, in-process R&D expenses were $6.3 million, and G&A expenses were $7.0 million. Net loss reported at $36.1 million.
The company is focusing on developing a broad pipeline of oncology therapies, including ADCs and small molecules, supported by business development efforts and focused research.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
What does Immunome, Inc. specialize in?
What is the core technology platform of Immunome?
What are the primary focus areas for Immunome?
Can you name some of Immunome's key pipeline assets?
Where is Immunome, Inc. based?
What is the goal of Immunome's development strategy?
How does Immunome identify high-affinity antibodies?
What distinguishes Immunome's approach to immunotherapy?
How does Immunome plan to impact cancer treatment?
What recent achievements has Immunome made?
